MBX Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
MBX$56.33+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(Unaudited - in thousands, except share and per share amounts)
| Three months endedSeptember 30, | Nine months endedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses | ||||
| Research and development | $32,048 | $19,270 | $81,507 | $59,400 |
| General and administrative | 34,295 | 4,656 | 53,032 | 12,860 |
| Total operating expenses | 66,343 | 23,926 | 134,539 | 72,260 |
| Loss from operations | (66,343) | (23,926) | (134,539) | (72,260) |
| Interest and other income, net | 3,922 | 2,308 | 11,506 | 7,351 |
| Net loss | $(62,421) | $(21,618) | $(123,033) | $(64,909) |
| Unrealized (loss) gain on marketable securities | (736) | 143 | (2,244) | 99 |
| Total other comprehensive (loss) gain | (736) | 143 | (2,244) | 99 |
| Total comprehensive loss | $(63,157) | $(21,475) | $(125,277) | $(64,810) |
| Net loss attributable to common stockholders | $(62,421) | $(21,618) | $(123,033) | $(64,909) |
| Net loss per common share, basic and diluted | $(1.29) | $(0.63) | $(2.58) | $(1.93) |
| Weighted average number of common shares outstanding used in computation of net loss per common share, basic and diluted | 48,559,266 | 34,198,597 | 47,617,875 | 33,688,669 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.